Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Biogen strikes deal with Versant-backed biotech to expand immune portfolio
Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page